LON:ERGO Ergomed - ERGO Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ergomed plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 992 -36.00 (-3.50%) (As of 03/28/2023 04:52 PM ET) Add Compare Share Share Today's Range 988▼ 1,038.5050-Day Range 997▼ 1,31452-Week Range 910▼ 1,478Volume253,290 shsAverage Volume124,572 shsMarket Capitalization£499.97 millionP/E Ratio3,815.38Dividend YieldN/APrice TargetGBX 1,525 ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines Ergomed MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside53.7% UpsideGBX 1,525 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 stars 3.3 Analyst's Opinion Consensus RatingErgomed has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,525, Ergomed has a forecasted upside of 53.7% from its current price of GBX 992.Amount of Analyst CoverageErgomed has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ERGO. Previous Next 0.0 Dividend Strength Dividend YieldErgomed does not currently pay a dividend.Dividend GrowthErgomed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERGO. Previous Next 1.8 News and Social Media Coverage News SentimentErgomed has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ergomed this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ergomed insiders have not sold or bought any company stock.Percentage Held by Insiders19.47% of the stock of Ergomed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.09% of the stock of Ergomed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Ergomed is 3,815.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 116.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Ergomed is 3,815.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 95.61.Price to Book Value per Share RatioErgomed has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ergomed (LON:ERGO) StockErgomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.Read More Receive ERGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter. Email Address ERGO Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comShore Capital Reiterates Hold Rating for Ergomed (LON:ERGO)March 23, 2023 | americanbankingnews.comErgomed (LON:ERGO) Rating Reiterated by Berenberg BankMarch 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 22, 2023 | finance.yahoo.comErgomed Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2023 | finance.yahoo.comEstimating The Fair Value Of Ergomed plc (LON:ERGO)February 26, 2023 | msn.comJust released: the 3 best small-cap stocks to buy now [PREMIUM PICKS]February 21, 2023 | marketwatch.comPharmacovigilance Outsourcing Market 2023 Size, Share, Growth, Analysis, Trends and Forecast to 2028February 20, 2023 | finance.yahoo.comIf EPS Growth Is Important To You, Ergomed (LON:ERGO) Presents An OpportunityMarch 28, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!January 25, 2023 | morningstar.comEasyJet Shares Jump After Upbeat 1Q, Strong OutlookJanuary 25, 2023 | marketwatch.comErgomed Sees 2022 Adjusted Earnings Meeting Market Views; Names New CFOJanuary 23, 2023 | finance.yahoo.comWhen Should You Buy Ergomed plc (LON:ERGO)?December 28, 2022 | uk.finance.yahoo.comErgomed plc (ERGO.L)November 28, 2022 | finance.yahoo.comAre Robust Financials Driving The Recent Rally In Ergomed plc's (LON:ERGO) Stock?November 21, 2022 | markets.businessinsider.comErgomed (ERGO): Two key management changesNovember 17, 2022 | marketwatch.comErgomed Names Jonathan Curtain as Deputy CFOOctober 30, 2022 | finance.yahoo.comThe 9.0% return this week takes Ergomed's (LON:ERGO) shareholders five-year gains to 484%October 10, 2022 | finance.yahoo.comIs There An Opportunity With Ergomed plc's (LON:ERGO) 29% Undervaluation?October 4, 2022 | markets.businessinsider.comErgomed (ERGO): Poised for a strong FY22September 13, 2022 | finance.yahoo.comDoes Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?September 8, 2022 | markets.businessinsider.comDeka Biosciences Appoints Chief Medical Officer and Vice President of Clinical OperationsAugust 14, 2022 | finance.yahoo.comIs There Now An Opportunity In Ergomed plc (LON:ERGO)?August 1, 2022 | markets.businessinsider.comErgomed (ERGO): Sustained growth momentum in H122July 28, 2022 | lse.co.ukErgomed posts strong growth after Adamas acquisitionJuly 27, 2022 | proactiveinvestors.comErgomed revenues rise 25% as pharma services demand stays healthyJuly 27, 2022 | marketwatch.comErgomed Expects 2022 Performance in Line With Market ViewsJune 18, 2022 | finance.yahoo.comErgomed plc (LON:ERGO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ERGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter. Email Address ERGO Company Calendar Last Earnings9/18/2017Today3/28/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ERGO CUSIPN/A CIKN/A Webwww.ergomedplc.com Phone+44-1483-503205FaxN/AEmployees1,371Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 1,525 High Stock Price ForecastGBX 1,600 Low Stock Price ForecastGBX 1,450 Forecasted Upside/Downside+53.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.26 Trailing P/E Ratio3,811.54 Forward P/E Ratio24.08 P/E GrowthN/ANet Income£13.36 million Net Margins10.08% Pretax MarginN/A Return on Equity19.93% Return on Assets11.87% Debt Debt-to-Equity Ratio3.45 Current Ratio1.26 Quick Ratio1.22 Sales & Book Value Annual Sales£132.46 million Price / Sales3.77 Cash FlowGBX 18.13 per share Price / Cash Flow54.67 Book ValueGBX 150 per share Price / Book6.61Miscellaneous Outstanding Shares50,400,000Free FloatN/AMarket Cap£499.46 million OptionableNot Optionable Beta0.88 Key ExecutivesDr. Miroslav Reljanovic (Age 64)Founder & Exec. Chairman Comp: $641.1kMr. Richard T. Barfield (Age 65)CFO & Exec. Director Comp: $438.78kMr. Michael William Spiteri (Age 62)Chief Transformation & Technology Officer Comp: $60kMr. Shaun HopgoodChief Information OfficerDr. Michael ForstnerHead of Risk Management & PharmacoepidemiologyMs. Sally AmanuelPres of PrimeVigilanceDr. Gordana TonkovicPres of Clinical ResearchMs. Ronel SteynSr. VP of Global Devel.Keith ByrneSr. Vice-Pres of Capital Markets & StrategyJonathan CurtainDeputy CFOMore ExecutivesKey CompetitorsSilence TherapeuticsLON:SLNPureTech HealthLON:PRTCOxford BiomedicaLON:OXBHorizon Discovery Group plc (HZD.L)LON:HZDVerona Pharma plc (VRP.L)LON:VRPView All CompetitorsInsidersRichard BarfieldSold 125,000 sharesTotal: £168.13 M ($1,345.00/share)Richard BarfieldSold 25,000 sharesTotal: £29.25 M ($1,170.00/share)View All Insider Transactions ERGO Stock - Frequently Asked Questions Should I buy or sell Ergomed stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ergomed in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ERGO shares. View ERGO analyst ratings or view top-rated stocks. What is Ergomed's stock price forecast for 2023? 3 equities research analysts have issued 12-month price objectives for Ergomed's shares. Their ERGO share price forecasts range from GBX 1,450 to GBX 1,600. On average, they anticipate the company's share price to reach GBX 1,525 in the next twelve months. This suggests a possible upside of 53.9% from the stock's current price. View analysts price targets for ERGO or view top-rated stocks among Wall Street analysts. How have ERGO shares performed in 2023? Ergomed's stock was trading at GBX 1,272 at the beginning of the year. Since then, ERGO shares have decreased by 22.1% and is now trading at GBX 991. View the best growth stocks for 2023 here. How were Ergomed's earnings last quarter? Ergomed plc (LON:ERGO) announced its quarterly earnings results on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The firm earned $22.91 million during the quarter. Ergomed had a trailing twelve-month return on equity of 19.93% and a net margin of 10.08%. What other stocks do shareholders of Ergomed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), Axsome Therapeutics (AXSM), FuelCell Energy (FCEL), NIO (NIO), Science Applications International (SAIC), Northern Dynasty Minerals (NAK), Tilray (TLRY), Agilent Technologies (A) and American Express (AXP). What is Ergomed's stock symbol? Ergomed trades on the London Stock Exchange (LON) under the ticker symbol "ERGO." How do I buy shares of Ergomed? Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Ergomed's stock price today? One share of ERGO stock can currently be purchased for approximately GBX 991. How much money does Ergomed make? Ergomed (LON:ERGO) has a market capitalization of £499.46 million and generates £132.46 million in revenue each year. The company earns £13.36 million in net income (profit) each year or GBX 0.26 on an earnings per share basis. How many employees does Ergomed have? The company employs 1,371 workers across the globe. How can I contact Ergomed? Ergomed's mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The official website for the company is www.ergomedplc.com. The company can be reached via phone at +44-1483-503205. This page (LON:ERGO) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.